CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
A Study of Durvalumab and BA3011 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy
A Study of Durvalumab and BA3021 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Overexpressing Advanced Gastroesophageal Adenocarcinoma
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS =18 Breast Cancer (DEBRA)
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
At the recent European Society For Medical Oncology (ESMO 21) Congress held September 16 -21, Dr. Thierry Conroy presented the updated results of Unicancer PRODIGE 24/CCTG PA6 trial. The five-year data from the trail has confirmed the significant benefits in all outcomes. This practice-changing research confirmed the significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy regimen compared to the then standard treatment with gemcitabine.
After surgery, two out of five patients treated with mFOLFIRINOX did not experience disease relapse compared to one out of five in those treated with gemcitabine. In addition, the survival of patients was significantly improved; about two out of three patients were alive in the mFOLFIRINOX arm versus one in two in the gemcitabine arm after three years.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
The practice changing CCTG SC24 randomized phase II/III trial is the first to show that stereotactic body radiation therapy (SBRT) is superior to conventional radiation treatments in alleviating pain from spinal metastases. Findings from the International trial have been published in Lancet Oncology.
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
The Breast 59: 327 - 338, 2021Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;S?tersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Borrego MR;Moore HC;Saunders C;Cardoso F;Susnjar S;Bjelic-Radisic V;Smith KL;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;
Current Oncology 28: 2830 - 2839, 2021Xu RY;Kato D;Pond GR;Sundquist S;Schoales J;Lalani S;Dancey JE;
J Am Med Assoc 325: 1277 - 1286, 2021Meyerhardt JA;Shi Q;Fuchs CS;Meyer J;Niedzwiecki D;Zemla T;Kumthekar P;Guthrie KA;Couture F;Kuebler P;Bendell JC;Kumar P;Lewis D;Tan B;Bertagnolli M;Grothey A;Hochster HS;Goldberg RM;Venook A;Blanke C;O'Reilly EM;Shields AF;
Melanoma Research 31: 27 - 37, 2021Bao R;Surriga O;Olson DJ;Allred JB;Strand CA;Zha Y;Carll T;Labadie BW;Bastos BR;Butler M;Hogg D;Musi E;Ambrosini G;Munster P;Schwartz GK;Luke JJ;
J Clin Oncol 39: 117 - 117, 2021Topham JT;O'Callaghan CJ;Feilotter H;Kennecke HF;Lee YS;Li W;Banks K;Renouf DJ;Jonker D;Tu D;Chen EX;Loree JM;
European Urology 80: 275 - 279, 2021Sweeney CJ;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx GM;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Davis ID;
Nature Medicine 27: 1432 - 1441, 2021Andrews MC;Duong CPM;Gopalakrishnan V;Iebba V;Chen WS;Derosa L;Khan MAW;Cogdill AP;White MG;Wong MC;Ferrere G;Fluckiger A;Roberti MP;Opolon P;Alou MT;Yonekura S;Roh W;Spencer CN;Curbelo IF;Vence L;Reuben A;Johnson S;Arora R;Morad G;Lastrapes M;Baruch EN;Little L;Gumbs C;Cooper ZA;Prieto PA;Wani K;Lazar AJ;Tetzlaff MT;Hudgens C;Callahan MK;Adamow M;Postow MA;Ariyan CE;Gaudreau PO;Nezi L;Raoult D;Mihalcioiu C;Elkrief A;Pezo RC;Haydu LE;Simon JM;Tawbi HA;McQuade J;Hwu P;Hwu WJ;Amaria RN;Burton EM;Woodman SE;Watowich S;Diab A;Patel SP;Glitza IC;Wong MK;Zhao L;Zhang J;Ajami NJ;Petrosino J;Jenq RR;Davies MA;Gershenwald JE;Futreal PA;Sharma P;Allison JP;Routy B;Zitvogel L;Wargo JA;